SCHEMBL498590

SCHEMBL498590

Nc1ccc(C(=O)O)cc1C(F)(F)F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 1/20 0.50
LMNA P02545 1/20 0.47
KDM4E B2RXH2 4/20 0.44
ALDH1A1 P00352 3/20 0.44
HPGD P15428 3/20 0.44
HSD17B10 Q99714 2/20 0.44
RXRA P19793 1/20 0.44
RXRB P28702 1/20 0.44
RXRG P48443 1/20 0.44
SRD5A2 P31213 2/20 0.44
P4HB P07237 1/20 0.43
FFAR4 Q5NUL3 2/20 0.43
TTR P02766 1/20 0.42
AR P10275 1/20 0.42
ADH5 P11766 1/20 0.42
DDR1 Q08345 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GAA P10253 3/20 0.41
MAPT P10636 3/20 0.41
THRB P10828 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29518166 1.00 CDC25B (0.50) CDC25BLMNAKDM4EALDH1A1HPGD
SCHEMBL3198016 0.86 AR (0.43) LMNAALDH1A1HSD17B10SRD5A2FFAR4
SCHEMBL30469486 0.86 AR (0.43) LMNAALDH1A1HSD17B10SRD5A2FFAR4
SCHEMBL6815102 0.85 AR (0.42) KDM4EALDH1A1HSD17B10FFAR4AR
SCHEMBL403027 0.85 CDC25B (0.46) CDC25BLMNAKDM4EALDH1A1HPGD
SCHEMBL29835211 0.85 CDC25B (0.46) CDC25BLMNAKDM4EALDH1A1HPGD
SCHEMBL28503435 0.83 DDR1 (0.43) KDM4EALDH1A1HPGDHSD17B10FFAR4
SCHEMBL6315471 0.83 KIF11 (0.50) FFAR4ARDDR1SMN1; SMN2MAPT
SCHEMBL7871444 0.82 PBRM1 (0.51) LMNAALDH1A1HPGDHSD17B10SRD5A2
SCHEMBL31319449 0.82 RXRA (0.48) KDM4ERXRARXRBRXRGSRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116178689-A Liquid crystal polymer and preparation method and application thereof 深圳大学 2023-05-30 CN claimed
WO-2022155357-A1 POLY(IMIDE-OXADIAZOLE) MEMBRANES FOR GAS SEPARATION APPLICATIONS SAUDI ARABIAN OIL COMPANY (SA) 2022-07-21 WO claimed
US-20220219127-A1 POLY(IMIDE-OXADIAZOLE) MEMBRANES FOR GAS SEPARATION APPLICATIONS SAUDI ARABIAN OIL COMPANY (SA) 2022-07-14 US claimed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 EP disclosed
WO-2025243317-A1 SUBSTITUTED BICYCLIC SULFONAMIDE DERIVATIVES AS MODULATORS OF CBL-B JUBILANT BIOSYS LIMITED (IN) 2025-11-27 WO disclosed
US-20250115608-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS ARDELYX, INC. (US) 2025-04-10 US disclosed
CN-119371391-A Aroyl compound and preparation method and application thereof 河北医科大学 2025-01-28 CN disclosed
US-12209088-B2 Hormone receptor modulators for treating metabolic conditions and disorders ARDELYX, INC. (US) 2025-01-28 US disclosed
US-20240391940-A1 FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME GENEROS BIOPHARMA LTD. (GB) 2024-11-28 US disclosed
US-11896936-B2 Poly(imide-oxadiazole) membranes for gas separation applications SAUDI ARABIAN OIL COMPANY (SA) 2024-02-13 US disclosed
EP-0632038-B1 METHOTREXATE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2001-08-22 EP disclosed
EP-1064298-A2 INHIBITORS OF CASPASES Vertex Pharmaceuticals Incorporated (US) 2001-01-03 EP disclosed
WO-1999047545-A2 INHIBITORS OF CASPASES VERTEX PHARMACEUTICALS INCORPORATED (US) 1999-09-23 WO disclosed
EP-0831845-A4 DIPHOSPHONATE DERIVATIVES OF THERAPEUTIC AGENTS ELIZANOR BIOPHARMACEUTICALS IN (US) 1998-12-02 EP disclosed
CN-1039907-C Methotrexate derivative CHUGAI PHARMACEUTICAL CO LTD (JP) 1998-09-23 CN disclosed
EP-0831845-A1 DIPHOSPHONATE DERIVATIVES OF THERAPEUTIC AGENTS Elizanor Biopharmaceuticals, Inc. (US) 1998-04-01 EP disclosed
WO-1996040156-A1 DIPHOSPHONATE DERIVATIVES OF THERAPEUTIC AGENTS ELIZANOR BIOPHARMACEUTICALS, INC. (US) 1996-12-19 WO disclosed
EP-0632038-A1 METHOTREXATE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 1995-01-04 EP disclosed
CN-1077956-A METHOTREXATE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 1993-11-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH CDC25B 3611/4885LMNA 1988/4885KDM4E 3565/4885
US-12209088-B2 Hormone receptor modulators for treating metabolic conditions and disorders NR1H4, FXR1, GLP1R CDC25B 1914/4885LMNA 4357/4885KDM4E 4023/4885
US-20240391940-A1 FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME STAT5A, STAT5B, JAK2 CDC25B 962/4885LMNA 4799/4885KDM4E 1526/4885
US-20250115608-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS NR1H4, FXR1, GLP1R CDC25B 1914/4885LMNA 4357/4885KDM4E 4023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.